Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 729 across all filing types
Latest filing 2022-01-05 Director's Dealing
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：授出购股权
Director's Dealing Classification · 95% confidence The document is a formal announcement regarding the granting of stock options under the company's 2016 Option and Incentive Plan. It details the number of options granted, exercise price, vesting schedule, and related terms. The document is issued by the company's board remuneration committee and includes definitions and regulatory references. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report but an announcement of a share-based compensation event. This fits the category of Director's Dealing or related insider transactions, but since the recipients are employees and not directors or major shareholders, it is more aligned with announcements of share option grants. The closest fitting category is Director's Dealing (DIRS), which covers personal share transactions by company directors and executives, including share option grants. Confidence is high given the detailed description of share option grants and the absence of other report types.
2022-01-05 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document includes detailed tables of share issuance, dates, prices, and percentages, as well as confirmations that the share issuances were authorized and complied with legal and listing requirements. The document is not an announcement of a report but the actual disclosure of share capital changes. This fits the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues or other capital changes. The document length is 3101 characters, which is sufficient for a substantive disclosure rather than a brief announcement. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2022-01-03 Chinese
百济神州有限公司关于超额配售选择权实施结果的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the implementation results of an over-allotment option (greenshoe option) related to a stock issuance by BeiGene Ltd. It details the number of shares issued, shares bought back by the underwriter, funds delivered to the investor protection fund, and changes in shareholding after the option exercise period ended. The document includes specific dates (e.g., December 20, 2021, December 27, 2021) and financial figures related to the share issuance and repurchase. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement about the completion and results of a capital market transaction involving share issuance and over-allotment option exercise. This fits the category of Capital/Financing Update (CAP). The document length is about 5,092 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report. Therefore, the classification is CAP with high confidence.
2021-12-26 Chinese
中国国际金融股份有限公司关于百济神州有限公司超额配售选择权实施情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from China International Capital Corporation Limited regarding the implementation of the over-allotment option (green shoe) for BeiGene, Ltd.'s initial public offering on the STAR Market. It includes specifics on the number of shares involved, the exercise of the over-allotment option, share lock-up periods, shareholder changes, and the use of proceeds. The document is not a brief announcement but a comprehensive verification opinion on the over-allotment option exercise, including detailed shareholding changes and financial figures related to the share buyback. It is not an earnings release, annual report, or a simple announcement. It is a specialized report related to capital issuance and share allotment activities, focusing on the over-allotment option implementation and share capital changes. This fits best under Capital/Financing Update (CAP) as it deals with share issuance, over-allotment option exercise, and related capital structure changes.
2021-12-22 Chinese
上海市方达律师事务所关于百济神州有限公司（BeiGene, Ltd.）首次公开发行人民币普通股（A股）股票超额配售选择权实施情况的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the implementation of an over-allotment option (greenshoe option) related to BeiGene, Ltd.'s initial public offering (IPO) of A shares on the STAR Market (科创板) of the Shanghai Stock Exchange. It details the exercise of the over-allotment option, share allotment, share lock-up periods, and the use of proceeds from the IPO. The document references specific regulatory rules and approvals related to the IPO and share issuance. It is not a financial report, earnings release, or management discussion, but a legal opinion on a capital market transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is substantial and contains detailed information on the share issuance and over-allotment exercise, confirming it is not merely an announcement or a brief notice. Therefore, the appropriate classification is CAP with high confidence.
2021-12-21 Chinese
美股公告：临时报告8-K表格
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) by BeiGene, Ltd. It reports a significant event dated December 19, 2021, specifically the signing of a major definitive agreement (a collaboration and licensing agreement with Novartis Pharma AG). The document includes detailed descriptions of the agreement terms, milestone payments, and strategic cooperation. It also contains a press release attached as Exhibit 99.1 announcing the collaboration. The 8-K form is used for current reports to disclose material events that shareholders should know about. This is not an annual or quarterly report, nor an earnings release or proxy statement. It is a current event disclosure about a material contract and related business developments. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories. The document length (11,702 characters) and content confirm it is a full 8-K report, not just a brief announcement or certification.
2021-12-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.